Business
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
Contrasts EsoCheck's powerful cell collection capabilities to "cruder, decades-old" technologies during comments on patient access to medical technology
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Contrasts EsoCheck's powerful cell collection capabilities to \"cruder, decades-old\" technologies during comments on patient access to medical technology innovation\nNEW YORK, Feb. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (\"PAVmed\"), today announced that its Chairman and Chief Executive Officer, Lishan Aklog, M.D., highlighted Lucid's EsoCheck® Cell Collection Device (\"EsoCheck\") during testimony before the U.S. House of Representatives' Committee on Small Business. Dr. Aklog was invited by the Congressional committee to testify on the importance of facilitating and protecting patient access to innovative life-enhancing and life-saving medical technology products, such as EsoCheck.\n\n \n \n \n \n \n \n\n \n\"EsoCheck is a deceptively simple tool which allows precise, targeted collection of lower esophageal cells for precancer testing,\" Dr. Aklog said. \"EsoCheck's gentle approach to noninvasive cell collection is a dramatic and elegant improvement over cruder, decades-old technology, which involves dragging a Brillo Pad-like 'sponge-on-a-string', indiscriminately scraping cells from the stomach, esophagus and mouth.\" Dr. Aklog further noted, in separate comments, that \"EsoCheck's advanced features are a major contributor to EsoGuard's unprecedented early precancer detection results.\" \nEsoCheck and its patented, groundbreaking Collect & Protect® technology was invented by physician scientists at Case Western Reserve University, licensed by Lucid in 2018, and received FDA clearance in 2019. Manufacturing was transferred to a high-volume, low-cost contract manufacturer in 2022. EsoCheck is a vitamin pill-sized capsule containing a soft silicone balloon attached to a thin silicone catheter. When the balloon is inflated, subtle ridges on its surface are exposed, which permit gentle swabbing of the cells from the lower esophagus where esophageal precancer and cancer occur. When deflated, the balloon retracts into the capsule, protecting the sample from dilution and contamination by cells outside the target area during retrieval. Collect & Protect® technology allows precise, anatomically targeted collection of esophageal cells in a doctor's ...